Invention Grant
- Patent Title: Halogenated xanthene composition and method for treating hematologic cancers
-
Application No.: US17890659Application Date: 2022-08-18
-
Publication No.: US12133840B2Publication Date: 2024-11-05
- Inventor: Eric A. Wachter , Dominic Rodrigues , Satbir Thakur , Lucy Swift , Chunfen Zhang , Mohit Jain , Aru Narendran
- Applicant: Provectus Pharmatech, Inc. , UTI Limited Partnership
- Applicant Address: US TN Knoxville; CA Calgary
- Assignee: Provectus Pharmatech, Inc.,UTI Limited Partnership
- Current Assignee: Provectus Pharmatech, Inc.,UTI Limited Partnership
- Current Assignee Address: US TN Knoxville; CA Calgary
- Agency: Husch Blackwell LLP
- Main IPC: A61K31/352
- IPC: A61K31/352 ; A61K9/00 ; A61K31/21 ; A61P35/00 ; C07K16/28

Abstract:
A method of treating a mammalian subject having hematologic, non-tumorous cancer cells is disclosed. The method comprises the steps of: (A) administering to such a mammalian subject a therapeutically effective amount of a halogenated xanthene, a pharmaceutically acceptable salt or a C1-C4 alkyl ester thereof as a first cancer cytotoxic agent dissolved or dispersed in a pharmaceutically acceptable aqueous medium. The mammalian subject is maintained for a period of time sufficient to induce death of hematologic, non-tumorous cancer cells. A contemplated administration is typically repeated. A contemplated treatment method can also be carried out in conjunction with administration to said mammalian subject of a second therapeutically effective amount of a second, differently-acting cancer cytotoxic agent dissolved or dispersed in a pharmaceutically acceptable medium. The second cancer cytotoxic agent can be a small molecule or an intact antibody or paratope-containing portion thereof.
Public/Granted literature
- US20240082206A1 Composition and Method for Treating Hematologic Cancers Public/Granted day:2024-03-14
Information query